Literature DB >> 18497503

Correlation of PET/CT findings and histopathology after neoadjuvant therapy in non-small cell lung cancer.

Christoph Poettgen1, Dirk Theegarten, Wilfried Eberhardt, Sabine Levegruen, Thomas Gauler, Thomas Krbek, Georgios Stamatis, Helmut Teschler, Hilmar Kuehl, Andreas Bockisch, Martin Stuschke.   

Abstract

OBJECTIVES: Prediction of histopathological response with PET/CT scans after neoadjuvant chemoradiotherapy is limited by confounding factors which have been evaluated in this analysis.
METHODS: (18)F-2-fluoro-2-deoxy-D-glucose (FDG)-PET/CT findings [standard uptake value (SUV), residual tumor volume] were correlated with histopathological parameters of the resection specimens (tumor cell density, necrosis, scar, macrophage infiltration) in patients with locally advanced non-small cell lung cancer (stage IIIA/IIIB) after neoadjuvant induction chemotherapy (platinum-based doublet) and concurrent chemoradiotherapy (cisplatin/vinorelbine/45 Gy).
RESULTS: Sixty patients [40 male/20 female, median age 56 years (34-78)] completed induction therapy, 46 patients (stage IIIA/IIIB: 16/30; squamous cell carcinoma 41%, adenocarcinoma 48%, large cell carcinoma 11%) were resected. Pathologic complete response of the primary tumor was observed in 19 patients (41%) with a broad range of SUV(mean) (0.4-9.8, mean 3.0) after neoadjuvant therapy. A high rate of histopathological complete remissions (44%) was observed in tumors with a postinduction SUV >2.5 and volumes larger than the median (7.9 cm(3)) before resection. SUV(mean) was positively correlated with the macrophage score (r = 0.39, p = 0.007) and tumor cell density (r = 0.32, p = 0.03).
CONCLUSIONS: These observations suggest that postinduction FDG uptake should be interpreted with caution in larger residual tumor volumes, since high SUV levels may be due to macrophage infiltration and not viable tumor tissue. 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18497503     DOI: 10.1159/000134474

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  14 in total

1.  Phase I trial of induction histone deacetylase and proteasome inhibition followed by surgery in non-small-cell lung cancer.

Authors:  David R Jones; Christopher A Moskaluk; Heidi H Gillenwater; Gina R Petroni; Sandra G Burks; Jennifer Philips; Patrice K Rehm; Juan Olazagasti; Benjamin D Kozower; Yongde Bao
Journal:  J Thorac Oncol       Date:  2012-11       Impact factor: 15.609

Review 2.  [Results of N1 and N2 surgery in non-small cell lung cancer].

Authors:  J Pfannschmidt; J Kollmeier
Journal:  Chirurg       Date:  2019-12       Impact factor: 0.955

3.  Radiomic phenotype features predict pathological response in non-small cell lung cancer.

Authors:  Thibaud P Coroller; Vishesh Agrawal; Vivek Narayan; Ying Hou; Patrick Grossmann; Stephanie W Lee; Raymond H Mak; Hugo J W L Aerts
Journal:  Radiother Oncol       Date:  2016-04-13       Impact factor: 6.280

Review 4.  The promise and pitfalls of positron emission tomography and single-photon emission computed tomography molecular imaging-guided radiation therapy.

Authors:  Richard L Wahl; Joseph M Herman; Eric Ford
Journal:  Semin Radiat Oncol       Date:  2011-04       Impact factor: 5.934

5.  Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy.

Authors:  Apar Pataer; Neda Kalhor; Arlene M Correa; Maria Gabriela Raso; Jeremy J Erasmus; Edward S Kim; Carmen Behrens; J Jack Lee; Jack A Roth; David J Stewart; Ara A Vaporciyan; Ignacio I Wistuba; Stephen G Swisher
Journal:  J Thorac Oncol       Date:  2012-05       Impact factor: 15.609

6.  Computed tomography RECIST assessment of histopathologic response and prediction of survival in patients with resectable non-small-cell lung cancer after neoadjuvant chemotherapy.

Authors:  William N William; Apar Pataer; Neda Kalhor; Arlene M Correa; David C Rice; Ignacio I Wistuba; John Heymach; J Jack Lee; Edward S Kim; Reginald Munden; Kathryn A Gold; Vassiliki Papadimitrakopoulou; Stephen G Swisher; Jeremy J Erasmus
Journal:  J Thorac Oncol       Date:  2013-02       Impact factor: 15.609

7.  Prognostic implications of volume-based measurements on FDG PET/CT in stage III non-small-cell lung cancer after induction chemotherapy.

Authors:  Michael Soussan; Kader Chouahnia; Jacques-Antoine Maisonobe; Marouane Boubaya; Véronique Eder; Jean-François Morère; Irène Buvat
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-01-11       Impact factor: 9.236

Review 8.  Proteomic and metabolic prediction of response to therapy in gastrointestinal cancers.

Authors:  Ken Herrmann; Axel Walch; Benjamin Balluff; Marc Tänzer; Heinz Höfler; Bernd J Krause; Markus Schwaiger; Helmut Friess; Roland M Schmid; Matthias P A Ebert
Journal:  Nat Clin Pract Gastroenterol Hepatol       Date:  2009-03

9.  18F-FDG PET/CT of Non-Small Cell Lung Carcinoma Under Neoadjuvant Chemotherapy: Background-Based Adaptive-Volume Metrics Outperform TLG and MTV in Predicting Histopathologic Response.

Authors:  Irene A Burger; Ruben Casanova; Seraina Steiger; Lars Husmann; Paul Stolzmann; Martin W Huellner; Alessandra Curioni; Sven Hillinger; C Ross Schmidtlein; Alex Soltermann
Journal:  J Nucl Med       Date:  2016-01-28       Impact factor: 10.057

Review 10.  Integrated imaging of non-small cell lung cancer recurrence: CT and PET-CT findings, possible pitfalls and risk of recurrence criteria.

Authors:  Andrea Caulo; Saeed Mirsadraee; Fabio Maggi; Lucia Leccisotti; Edwin J R van Beek; Lorenzo Bonomo
Journal:  Eur Radiol       Date:  2011-10-04       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.